Skip to main content

The Oncology Institute, Inc. (TOI) Stock Forecast

Data as of May 3, 2026

Healthcare · Current price $4.05 (+4.92%)

Consensus Target
$5.00
Upside
+23.5%
Analysts
4
Rating
Buy(2.00)

Price Target Range

Low $5.00High $5.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy4
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Nov 25, 2025Matthew SheaNeedham$5.00+23.5%

TOI vs Sector & Market

MetricTOIHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count4818
Target Upside+23.5%+1150.2%+14.9%
P/E Ratio-57.596.9231.19

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$153M$156M$158M3
2026-09-30$166M$169M$172M1
2026-12-31$176M$179M$182M2
2027-03-31$165M$168M$170M1
2027-06-30$191M$194M$197M2
2027-09-30$218M$222M$226M2
2027-12-31$227M$231M$235M1

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$-0.07$-0.06$-0.063
2026-09-30$-0.05$-0.05$-0.051
2026-12-31$-0.04$-0.04$-0.031
2027-03-31$0.00$0.00$0.000
2027-06-30$0.00$0.00$0.001
2027-09-30$0.00$0.00$0.001
2027-12-31$0.00$0.00$0.000

Frequently Asked Questions

What is the analyst consensus for TOI?

The consensus among 4 analysts covering The Oncology Institute, Inc. (TOI) is Buy with an average price target of $5.00.

What is the highest price target for TOI?

The highest price target for TOI is $5.00, set by Matthew Shea at Needham on 2025-11-25.

What is the lowest price target for TOI?

The lowest price target for TOI is $5.00, set by Matthew Shea at Needham on 2025-11-25.

How many analysts cover TOI?

4 analysts have issued ratings for The Oncology Institute, Inc. in the past 12 months.

Is TOI a buy or sell right now?

Based on 4 analyst ratings, TOI has a consensus rating of Buy (2.00/5) with a +23.5% upside to the consensus target of $5.00.

What are the earnings estimates for TOI?

Analysts estimate TOI will report EPS of $-0.06 for the period ending 2026-06-30, with revenue estimated at $156M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.